Lupin Secures Exclusive India Deal for Diabetes, Obesity Drug Bofanglutide

• Lupin inks exclusive licensing, supply, and distribution deal with Gan & Lee Pharmaceuticals for GLP-1 drug Bofanglutide in India.
• Bofanglutide is a fortnightly injectable for Type 2 diabetes and weight management, offering less frequent dosing.
• The drug is potentially first-in-class globally, with efficacy comparable or better than existing GLP-1s.
• Deal strengthens Lupin's diabetes portfolio and accelerates its entry into the obesity treatment segment.
• Lupin shares are in focus following the announcement, despite a recent 1.4% decline.

Why It Matters: Lupin's strategic deal for Bofanglutide boosts its market presence in diabetes and obesity management.